Sunshine Biopharma Inc. and the University of Arizona have published new research findings in the Journal of Medicinal Chemistry detailing the efficacy of MR1-114, a novel PLpro inhibitor, against SARS-CoV-2 variants. The study demonstrates that MR1-114 exhibits nanomolar potency in vitro against at least three variants of the virus, including the original Washington Strain, Delta, and Omicron BA.5. In vivo results from a mouse model of SARS-CoV-2 infection indicate that repeated oral administration of MR1-114 significantly suppressed pulmonary viral replication and prevented disease-associated weight loss, matching the therapeutic efficacy of Nirmatrelvir.

The research highlights MR1-114's broad-spectrum activity and desirable ADME profile, including high oral bioavailability and preferential enrichment in the lungs of mice and rats. The compound targets two vulnerabilities remote from the catalytic site of the PLpro protease: the BL2 groove and the cryptic Val70Ub pocket. This approach addresses the challenge posed by PLpro's featureless active site, which has historically hindered the development of effective inhibitors.

Key Findings from the Study

Dr. Gregory Thatcher, pharmacology professor at the University of Arizona, emphasized the importance of the support from Sunshine Biopharma in exploring antiviral agents for future outbreaks. Dr. Rui Xiong, assistant professor in the Department of Pharmacology & Toxicology, noted that MR1-114 and its analogs offer a promising new strategy for targeting PLpro and could complement existing SARS-CoV-2 antivirals.

Dr. Steve Slilaty, CEO of Sunshine Biopharma and co-author of the publication, expressed delight in collaborating with the University of Arizona researchers. He stated that the publication reflects the company's commitment to advancing science and improving patient outcomes, underscoring the potential of MR1-114 to transform the treatment landscape for SARS Coronavirus infections. The company looks forward to further exploring the compound's capabilities and clinical development.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada, with approximately 12 additional drugs scheduled for launch in the remainder of 2026. Its proprietary drug development program includes K1.1 mRNA for liver cancer and the PLpro protease inhibitor for SARS Coronavirus infections.

Sunshine Biopharma Inc. has received approval for its 1mg generic Anastrozole tablets for the Canadian market, expanding its portfolio of specialty prescription medications. Anastrozole is the generic equivalent of the brand name breast cancer drug Arimidex. This approval positions the company to participate in a market segment projected to grow significantly over the next decade.

Anastrozole functions as a non-steroidal aromatase inhibitor, lowering estrogen levels in the body to slow or reverse the growth of specific breast tumors. It serves as standard care for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The drug's therapeutic application addresses a critical need in oncology treatment.

Market Projections

The global market for Anastrozole is expected to witness substantial growth in the coming years. According to The Insight Partners, the market size is projected to reach $2.53 billion by 2034, rising from $1.27 billion in 2025. This growth represents a compound annual growth rate (CAGR) of 7.97% during the forecast period from 2026 to 2034.

Canadian Pharmaceutical Landscape

The Canadian pharmaceutical market represents a significant portion of the global industry. Data from IQVIA Pharmafocus 2028 indicates that Canada accounts for approximately 2.1% of the global pharmaceutical market. The country ranks as the sixth largest pharmaceutical market globally, providing a substantial commercial opportunity for the newly approved product.